Ozempic's Success in Kidney Trial Impacts Dialysis Stocks
TL;DR Summary
Bloomberg's website is displaying a message asking users to ensure their browser supports JavaScript and cookies, and that they are not blocking them from loading. The message provides a reference ID for users to contact the support team for assistance.
- Ozempic Hit for DaVita (DVA), Baxter (BAX) Stocks May Last Through 2023 Bloomberg
- Novo Nordisk stops Ozempic kidney trial after early signs of success Reuters
- Ozempic's early success in kidney disease trial drags on dialysis stocks Yahoo Finance
- Ozempic Is Moving a Bunch of Stocks Wednesday Morning The Motley Fool
- Obesity revolution gorges on dialysis maker Reuters
Reading Insights
Total Reads
0
Unique Readers
15
Time Saved
0 min
vs 1 min read
Condensed
30%
57 → 40 words
Want the full story? Read the original article
Read on Bloomberg